These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10620455)

  • 1. Failure of goserelin ovarian ablation in premenopausal women with breast cancer: two case reports.
    Jiménez-Gordo AM; de las Heras B; Zamora P; Espinosa E; González-Barón M
    Gynecol Oncol; 2000 Jan; 76(1):126-7. PubMed ID: 10620455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature.
    Hill N; Madarnas Y
    Breast Cancer Res Treat; 2011 Aug; 129(1):265-8. PubMed ID: 21541703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
    Sverrisdottir A; Nystedt M; Johansson H; Fornander T
    Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women.
    Jonat W
    Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):1-5. PubMed ID: 11900209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
    Gerber B; von Minckwitz G; Stehle H; Reimer T; Felberbaum R; Maass N; Fischer D; Sommer HL; Conrad B; Ortmann O; Fehm T; Rezai M; Mehta K; Loibl S;
    J Clin Oncol; 2011 Jun; 29(17):2334-41. PubMed ID: 21537042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of goserelin in the treatment of breast cancer.
    Rody A; Loibl S; von Minckwitz G; Kaufmann M
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of ovarian ablation in the management of breast cancer.
    Wirk B
    Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adjuvant chemotherapy of premenopausal breast cancer with LH-RH analogue for ovarian protection--a case report].
    Asaga S; Ando J; Arai T; Fujii H
    Gan To Kagaku Ryoho; 2005 Jul; 32(7):1069-72. PubMed ID: 16044976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drawbacks of ovarian ablation with goserelin in women with breast cancer].
    Franco S; Lupa P; Guerra C; Pereira L; Oliveira CF
    Acta Med Port; 2005; 18(2):123-7. PubMed ID: 16202345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).
    von Minckwitz G; Graf E; Geberth M; Eiermann W; Jonat W; Conrad B; Brunnert K; Gerber B; Vescia S; Wollert J; Kaufmann M
    Eur J Cancer; 2006 Aug; 42(12):1780-8. PubMed ID: 16765589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
    J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study.
    Hughes LL; Gray RJ; Solin LJ; Robert NJ; Martino S; Tripathy D; Ingle JN; Wood WC; ; ; ;
    Cancer; 2004 Sep; 101(5):969-72. PubMed ID: 15329905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
    Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
    Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of premenopausal stage IV breast cancer responding to neoadjuvant endocrine therapy after chemotherapy with FEC].
    Konishi K; Hasegawa N; Kaneko H; Iimura Y; Shoji Y; Kawabata M
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):111-3. PubMed ID: 20087042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
    Urruticoechea A; Arnedos M; Walsh G; Dowsett M; Smith IE
    Breast Cancer Res Treat; 2008 Aug; 110(3):411-6. PubMed ID: 17851753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea.
    Kim HJ; Lee JS; Park EH; Lim WS; Sei JY; Koh BS; Son BH; Ahn JH; Jeong KH; Kim SB; Ahn SH
    Eur J Surg Oncol; 2009 Sep; 35(9):936-41. PubMed ID: 19269125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of premenopausal women with early-stage breast cancer: is there a role for ovarian suppression?
    Baum M; O'Shaughnessy JA
    Clin Breast Cancer; 2002 Oct; 3(4):260-7. PubMed ID: 12425754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.